Hidradenitis Suppurativa (HS) Treatment Market Snapshot (2023 to 2033)

The global hidradenitis suppurativa (HS) treatment market is expected to surpass an impressive valuation of USD 763.6 million in 2023 and is projected to reach USD 1,240.9 million by 2033, expected to register a CAGR of 4.97%.

Revenue growth of the global Hidradenitis suppurativa (HS) treatment market is significantly propelled by factors such as the increasing prevalence of chronic diseases, rapid advancements in the healthcare and medical sector, high adoption of the latest tools and techniques, and increasing funds by several public and private sectors.

In addition, growing focus on drug development, rising demand for precision medicine, high adoption of home care settings and point-of-care diagnostics, and growing investments in research and development activities are anticipated to drive global market revenue growth during the forecast period.

Report Attribute Details
Expected Market Value (2023) USD 763.6 million
Anticipated Forecast Value (2033) USD 1240.9 million
Projected Growth Rate (2023 to 2033) CAGR 4.97%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Hidradenitis suppurativa (HS) treatment Demand Analysis vs. Forecast 2023 to 2033

The market for Hidradenitis suppurativa (HS) treatment was worth USD 640 million in 2018 while growing at a CAGR of 3.59% during the historical period.

InflaRx's lead drug candidate, vilobelimab (IFX-1), is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Hidradenitis suppurativa (HS) treatment (HS), a chronic debilitating systemic skin disease. The Company received scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval in July 2020. The Company is working diligently to address the feedback received from the agencies and analyzing the strategy for its Phase III development in HS.

Considering the arrival of new drugs and other factors, the industry of Hidradenitis suppurativa (HS) treatment is projected to grow at 4.97% CAGR, reaching USD 1240.9 million by end of the forecast period.

Which are Some Prominent Drivers of the Hidradenitis Suppurativa (HS) Treatment Market?

Adoption of pipeline therapies to propel market growth

Adoption of key Hidradenitis suppurativa (HS) treatment pipeline therapies such as Bermekimab (MABp1), IFX-1, INCB054707, Secukinumab, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody, Avacopan, Bimekizumab, and others are under different phases of clinical trials for Hidradenitis suppurativa (HS) treatment. Thus, leading to market expansion during the forecast period.

On the other hand, topline data from the AURORA Phase II clinical trial of Avacopan in Hidradenitis suppurativa (HS) treatment demonstrated a statistically significant higher response with avacopan at 30 mg BID than placebo in the pre-specified Hurley Stage III (severe) Hidradenitis suppurativa (HS) treatment patients, which will further drive market growth.

Moreover, chemoCentryx plans to advance Avacopan into Phase III development for the treatment of patients with the most severe form of Hidradenitis suppurativa (HS) treatment. Thus, augmenting the market growth.

Also, Orismilast, Type 4 cyclic nucleotide phosphodiesterase inhibitors are being developed by Union Therapeutics for psoriasis, atopic dermatitis, and hidradenitis suppurative (HS) treatment which will fuel market expansion during the projected timeline.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

High cost of treatment, delay in treatment restraining industry’s growth

The high cost associated with treatment is expected to challenge the growth of the market. Also, the dearth of healthcare infrastructure in developing economies and the delay in the procedure of treatment completion may be due to the unawareness of the disease to physicians.

This will challenge the hidradenitis suppurativa (HS) treatment market. Additionally, the lack of skilled professionals and side effects involved with the treatment will act as restraints and further restrict the growth of the market during the forecast period.

Region-Wise Insights

What is the growth outlook in North America?

North America dominates the market with the maximum share

The hidradenitis supportive treatment market in North America is expected to garner a valuation of USD 620.4 million with a CAGR of 4.2% during the forecast period. Thus, accounting for 50% market share by end of the forecast period.

The growth is attributable to the surging adoption of newer techniques in this region and the growing presence of major key players and well-established healthcare infrastructure. Furthermore, growth is also driven by factors such as a rise in dermatological infections, an increase in clinical practices, and clinically trained professionals.

What are the growth prospects in East Asia?

East Asia to drive growth at a Steady Pace

The market in East Asia is projected to grow at the fastest CAGR of 5.1% during the forecast period. Growth in the number of generic manufacturers and rising government initiatives in this region are propelling market growth. Also, the development of healthcare infrastructure will further fuel growth in this region.

The rise in inflammatory skin disease, healthcare awareness, and government support are leading to market expansion in this region. Additionally, continuous improvement in the life science industry and health services and the awareness of skin diseases and their treatment are factors contributing to the highest growth of this market.

Moreover, increasing incomes and the purchasing power of citizens are witnessing a significant growth rate in this market which is benefitting the market in this region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

By Treatment Type, which segment will possess a Significant Share?

Biologics propelling growth with maximum share

The biologics segment is expected to account for a share of 61.4% by the end of the forecast period. Humira (Abbvie) is the first and only approved drug for Moderate to Severe hidradenitis suppurativa (HS) treatment until now which will lead to the fastest acceleration of this segment.

The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and the availability of a robust pipeline of biologic drugs for hidradenitis suppurative (HS) treatment.

For instance, In July 2015, the European Commission approved Humira to treat moderate to severe hidradenitis suppurative (HS) treatment. Similarly, this drug was approved in the USA in September 2015. Moreover, Humira is the only drug in Japan for hidradenitis suppurative (HS) treatment indication which will drive the growth of this segment in Japan. The unavailability of other alternative drugs and faster approval rate of other biologics similar to ‘Humira’ are expected to fuel the growth of this segment in the forecast period.

Another biologic, ‘Metformin’ is also used to treat metabolic syndrome associated with hidradenitis suppurative (HS) treatment and has been reported to reduce hidradenitis suppurativa (HS) treatment disease activity effectively. This will aid in the segment’s growth during the forecast period.

Which segment is projected to dominate the market by distribution channel?

Hospital pharmacies lead the segment with a significant share

By distribution channel, the hospital pharmacies segment dominated the market in 2022, and this trend is projected to continue during the forecast period. This segment is anticipated to possess around 65% market share by end of 2033.

The growth is attributable to the rise in prices of drugs, rising income levels of poor & middle-class families, and faster approval of drugs. Moreover, an increasing number of initiatives from various governmental bodies in enhancing the infrastructure of hospitals and pharmacies are expected to boost the growth of the hospital pharmacies segment.

By route of administration, which segment is expected to dominate?

The topical route of administration driving growth with maximum share

This segment is anticipated to account for the maximum share of 68.5% by end of the forecast period. As topical medical yielded rapid and significant improvements in patients with moderate to severe hidradenitis suppurative (HS) treatment, it has witnessed higher demand in the hidradenitis suppurativa (HS) treatment market. This trend is most likely to remain the same during the forecast period.

Start-ups in Hidradenitis Suppurativa (HS) Treatment Market

  • Founded in 2018, HidraWear is a Galway, Ireland-based start-up that has developed a wearable wound care solution for treating individuals affected with hidradenitis suppurative (HS) treatment. The company has developed HidraWear dressings consisting of anti-strike through layers to capture the exudate within the dressing. It was granted funding of USD 56.1K from EIT health in July 2019.
  • Founded in 2020, Phoenicis is a United states-based developer of therapeutics for rare, genetic, and inflammatory disorders. The company is developing a pipeline for rare, genetic, and inflammatory disorders with a primary focus on skin disorders. The company's products include PTM-001 for Hidradenitis suppurativa (HS) treatment, PTW-002 for Dystrophic Epidermolysis Bullosa (DEB), and PTD-003 for Epidermolysis Bullosa.
  • Founded in 2019, Henlez is a Copenhagen, Denmark-based start-up. It is the developer of topical treatments for recurrent follicular skin problems. It offers a lead candidate HEN-001 which is an enzyme-based, topical for hidradenitis suppurative (HS) treatment which is a chronic inflammatory condition characterized by severe pain, malodorous drainage, and permanent scarring of the armpits and groin. It was granted funding of USD 1 million from Eir Ventures and Karolinska Development in October 2022.

Market Competition

The global Hidradenitis suppurativa (HS) treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

The major players in the market are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma SPRL, Janssen Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics/Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics.

Some recent developments in this industry are:

  • In June 2022, Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus were announced by Roivant and Pfizer.
  • In February 2021, AbbVie Inc. received FDA approval for HUMIRA (adalimumab), which can be used to treat moderate to severe hidradenitis suppurative (HS) treatment.
  • In March 2022, MoonLake started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurative (HS) treatment (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.

Report Scope

Report Attribute Details
Market Value in 2023 USD 763.6 million
Market Value in 2033 USD 1,240.9 million
Growth Rate CAGR of 4.97% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered

Clinical Stage, Treatment, Route of Administration, End User, Distribution Channel, Region

Regions Covered

North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa

Key Countries Profiled United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled

InflaRx N.V; Novartis A.G; Incyte Corporation; UCB Biopharma SPRL; Janssen Pharmaceuticals; Amgen Inc.; ChemoCentryx; Priovant Therapeutics; AnaptysBio; AbbVie Inc.; ACELYRIN; Aclaris Therapeutics Inc.; Boehringer Ingelheim; Eli Lilly and Company; MoonLake Immunotherapeutics; Aristea Therapeutics

Customization Available Upon Request

Key Segments Profiled in the Hidradenitis Suppurativa (HS) Treatment Market Industry Survey

By Clinical Stages:

  • Hurley Stage 1- Low
  • Hurley Stage 2- Moderate
  • Hurley Stage 3- High

By Treatment Type:

  • Medication
    • Biologics
    • Antibiotics
    • Hormonal Therapy
    • Immune Suppurativa Drugs
    • Zinc Supplements
    • Pain Medications
  • Surgery

By Route of Administration:

  • Oral
  • Tropical

By End Users:

  • Hospitals
  • Homecare
  • Specialty Clinics

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

What is the Market Projection for Hydradenitis Suppurative Market in North America?

The regional market to witness an absolute growth opportunity of USD 620.4 million through 2033.

Which Geographical Region would Captures a Greater Share of the Overall Market?

The regional market in East Asia is projected to follow 5.1% growth rate until 2033.

Why the Biologics Segment is getting Dominant over other Product Segments?

High efficacy and increased product approvals have strengthened this segment.

Which is the Most Favored Channel for the Distribution of HS Treatment Products?

The hospital pharmacies segment achieves around 65% of the global sales .

Which is the Best Performing Segment in terms of route of administration?

The topical route of administration to account for 68.5% of the global market share.

Table of Content
	1. Executive Summary
	2. Market Overview
	3. Market Background
	4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
	5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Clinical Stages
		5.1. Hurley Stage 1 - Low
		5.2. Hurley Stage 2 - Moderate
		5.3. Hurley Stage 3 - High
	6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
		6.1. Medication
			6.1.1. Biologics
			6.1.2. Antibiotics
			6.1.3. Hormonal Therapy
			6.1.4. Immune Suppurativa Drugs
			6.1.5. Zinc Supplements
			6.1.6. Pain Medications
		6.2. Surgery
	7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
		7.1. Oral
		7.2. Topical
	8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
		8.1. Hospitals
		8.2. Homecare
		8.3. Specialty Clinics
	9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
		9.1. Hospital Pharmacy
		9.2. Online Pharmacy
		9.3. Retail Pharmacy
	10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
		10.1. North America
		10.2. Latin America
		10.3. Europe
		10.4. South Asia
		10.5. East Asia
		10.6. Oceania
	11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	18. Key Countries Market Analysis
	19. Market Structure Analysis
	20. Competition Analysis
		20.1. InFlaRx N.V
		20.2. Novartis A.G.
		20.3. Incyte Corporation
		20.4. UCB Biopharma SPRL
		20.5. Janssen Pharmaceuticals
		20.6. Amgen Inc.
		20.7. ChemoCentryx
		20.8. Priovant Therapeutics
		20.9. AnaptysBio
		20.10. AbbVie Inc.
		20.11. ACELYRIN
		20.12. Aclaris Therapeutics Inc.
		20.13. Boehringer Ingelheim
		20.14. Eli Lilly & Company
		20.15. MoonLake Immunotherapeutics
		20.16. Aristea Therapeutics
	21. Assumptions & Acronyms Used
	22. Research Methodology
Recommendations

Healthcare

Atopic Dermatitis Treatment Market

August 2024

REP-GB-3097

317 pages

Healthcare

Moderate-to-Severe Acne Treatment Market

July 2023

REP-GB-8095

226 pages

Consumer Product

Anti-Acne Serum Market

April 2023

REP-GB-13334

250 pages

Consumer Product

Skin Care Devices Market

March 2023

REP-GB-13111

325 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Hidradenitis Suppurativa (HS) Treatment Market

Schedule a Call